Literature DB >> 30678413

[Report of cancer epidemiology in China, 2015].

R S Zheng1, K X Sun1, S W Zhang1, H M Zeng1, X N Zou1, R Chen1, X Y Gu2, W W Wei1, J He3.   

Abstract

Objective: Data from local cancer registries were pooled to estimate cancer incidence and mortality in China, 2015.
Methods: Data submitted from 501 cancer registries were checked & evaluated according to the criteria of data quality control, and 368 registries' data were qualified for the final analysis. Data were stratified by area (urban/rural), sex, age group and cancer sites, and combined with national population data to estimate cancer incidence and mortality in China, 2015. Chinese population census in 2000 and Segi's population were used for age-standardized.
Results: Total population covered by 368 cancer registries were 309 553 499 (148 804 626 in urban and 160 748 873 in rural areas). The percentage of morphologically verified cases (MV) and the percentage of death certificate-only cases (DCO) accounted for 69.34% and 2.09%, respectively, and the mortality to incidence ratio was 0.61. About 3 929 000 new cancer cases were reported in 2015 and the crude incidence rate was 285.83 per 100 000 population (males and females were 305.47 and 265.21 per 100 000 population). Age-standardized incidence rates by Chinese standard population (ASIRC) and by world standard population (ASIRW) were 190.64 and 186.39 per 100 000 population, respectively, with the cumulative incidence rate (0-74 age years old) of 21.44%. The cancer incidence and ASIRC were 304.96/100 000 and 196.09/100 000 in urban areas and 261.40/100 000 and 182.70/100 000 in rural areas, respectively. About 2 338 000 cancer deaths were reported in 2015 and the cancer mortality was 170.05/100 000 (210.10/100 000 in males and 128.00/100 000 in females). Age-standardized mortality rates by Chinese standard population (ASMRC) and by world standard population (ASMRW) were 106.72/100 000 and 105.84/100 000, respectively, with the cumulative incidence rate (0-74 age years old) of 11.94%. The cancer mortality and ASMRC were 172.61/100 000 and 103.65/100 000 in urban areas and 166.79/100 000 and 110.76/100 000 in rural areas, respectively. The most common cancer cases including lung, gastric, colorectal, liver and female breast, the top 10 cancer incidence accounted for about 76.70% of all cancer new cases. The most common cancer deaths including lung, liver, gastric, esophageal and colorectal, the top 10 cancer deaths accounted for about 83.00% of all cancer deaths. Conclusions: The burden of cancer showed a continuous upward trend in China. Cancer prevention and control faces the problem of the disparity in different areas and different cancer burden between men and women. The cancer pattern in China presents the coexistence of the cancer patterns in developed and developing countries. The situation of cancer prevention and control is still serious in China.

Entities:  

Keywords:  Cancer registry; China; Incidence; Mortality; Neoplasm

Mesh:

Year:  2019        PMID: 30678413     DOI: 10.3760/cma.j.issn.0253-3766.2019.01.005

Source DB:  PubMed          Journal:  Zhonghua Zhong Liu Za Zhi        ISSN: 0253-3766


  223 in total

1.  COVID-19 and Cancer: Lessons From a Pooled Meta-Analysis.

Authors:  Aakash Desai; Sonali Sachdeva; Tarang Parekh; Rupak Desai
Journal:  JCO Glob Oncol       Date:  2020-04

2.  21-Gene recurrence score influences the chemotherapy decision for patients with breast cancer of different luminal subtypes.

Authors:  Wei Wang; Lin Lin; Xiaochun Fei; Jin Hong; Weiqi Gao; Siji Zhu; Jiayi Wu; Ou Huang; Jianrong He; Yafen Li; Li Zhu; Weiguo Chen; Xiaosong Chen; Kunwei Shen
Journal:  Oncol Lett       Date:  2019-08-16       Impact factor: 2.967

3.  SNHG7 accelerates cell migration and invasion through regulating miR-34a-Snail-EMT axis in gastric cancer.

Authors:  Yangmei Zhang; Yuan Yuan; Youwei Zhang; Long Cheng; Xichang Zhou; Kai Chen
Journal:  Cell Cycle       Date:  2019-12-08       Impact factor: 4.534

4.  Evaluation of models for predicting the probability of malignancy in patients with pulmonary nodules.

Authors:  You Li; Hui Hu; Ziwei Wu; Ge Yan; Tangwei Wu; Shuiyi Liu; Weiqun Chen; Zhongxin Lu
Journal:  Biosci Rep       Date:  2020-02-28       Impact factor: 3.840

5.  Comparing EQ-5D-3L and EQ-5D-5L performance in common cancers: suggestions for instrument choosing.

Authors:  Juan Zhu; Xin-Xin Yan; Cheng-Cheng Liu; Hong Wang; Le Wang; Su-Mei Cao; Xian-Zhen Liao; Yun-Feng Xi; Yong Ji; Lin Lei; Hai-Fan Xiao; Hai-Jing Guan; Wen-Qiang Wei; Min Dai; Wanqing Chen; Ju-Fang Shi
Journal:  Qual Life Res       Date:  2020-09-15       Impact factor: 4.147

6.  Association of cancer prevention awareness with esophageal cancer screening participation rates: Results from a population-based cancer screening program in rural China.

Authors:  Shangchun Jia; He Li; Hongmei Zeng; Rongshou Zheng; Jiang Li; Jufang Shi; Zhixun Yang; Maomao Cao; Wanqing Chen
Journal:  Chin J Cancer Res       Date:  2019-08       Impact factor: 5.087

7.  Nomogram model characterized by mutant genes and clinical indexes to identify high-risk patients with stage III/IV colorectal cancer.

Authors:  Kai Liu; Cui Wang; Jiefu Wang; Yang Zhan; Xin Yue; Dalu Kong
Journal:  J Gastrointest Oncol       Date:  2020-12

8.  Variant of SNPs at lncRNA NEAT1 contributes to gastric cancer susceptibility in Chinese Han population.

Authors:  Xuanke Ji; Yali Yan; Nan Ma; Gui He; Kunyan Wang; Yuehua Zhang; Jingjing Yin; Chunhua Song; Peng Wang; Hua Ye; Liping Dai; Jianying Zhang; Kaijuan Wang
Journal:  Int J Clin Oncol       Date:  2021-01-19       Impact factor: 3.402

9.  Prolonged surveillance of colorectal cancer patients after curative surgeries beyond five years of follow-up.

Authors:  Lingheng Kong; Jianhong Peng; Jibin Li; Fulong Wang; Cong Li; Peirong Ding; Liren Li; Gong Chen; Xiaojun Wu; Zhenhai Lu; Yujing Fang; Zhizhong Pan; Desen Wan
Journal:  Ann Transl Med       Date:  2019-11

10.  Evaluation of Cell Surface Vimentin Positive Circulating Tumor Cells as a Diagnostic Biomarker for Lung Cancer.

Authors:  Xiaohong Xie; Liqiang Wang; Xinni Wang; Wan-Hung Fan; Yinyin Qin; Xinqing Lin; Zhanhong Xie; Ming Liu; Ming Ouyang; Shiyue Li; Chengzhi Zhou
Journal:  Front Oncol       Date:  2021-05-14       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.